Literature DB >> 3578373

Successful treatment of Pseudomonas peritonitis during continuous ambulatory peritoneal dialysis.

V Nguyen, R D Swartz, J Reynolds, D Wilson, F K Port.   

Abstract

Successful eradication of Pseudomonas peritonitis is described in 12 (57%) of 21 cases from a large continuous ambulatory peritoneal dialysis (CAPD) program at a tertiary care center. In successful cases, cure was achieved within 17 days using therapy which included aminoglycoside started routinely at the onset of symptoms and an antipseudomonal penicillin or cephalosporin derivative added as soon as pseudomonas infection was identified on culture. Of the 9 treatment failures which required catheter removal, 2 had failure of peritoneal drainage, 4 had infection with multiple and/or drug-resistant Pseudomonas strains, and 3 had persistent catheter tunnel infection which resulted in recurrent Pseudomonas peritonitis. Factors such as diabetes mellitus and pediatric age group did not prevent successful medical therapy. Predisposing factors favoring development of Pseudomonas peritonitis included technical failures and in a few cases recent antibiotic therapy. We conclude that Pseudomonas peritonitis complicating CAPD can be successfully cured without catheter removal or discontinuation of CAPD in many cases, particularly when complicating factors are not present.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3578373     DOI: 10.1159/000167427

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  2 in total

1.  Pseudomonas paucimobilis peritonitis in a patient on CAPD successfully treated with ciprofloxacin and netilmicin.

Authors:  G Phillips; L W Fleming; W K Stewart
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-08       Impact factor: 3.267

2.  In vitro bactericidal activities of gentamicin, cefazolin, and imipenem in peritoneal dialysis fluids.

Authors:  D C Halstead; J Guzzo; J A Giardina; A E Geshan
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.